Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Lung Neoplasms 76Leukemia, Myeloid, Acute 68Prostatic Neoplasms 66Carcinoma, Non-Small-Cell Lung 56Neoplasm Metastasis 55Breast Neoplasms 51Multiple Myeloma 42Colorectal Neoplasms 40Pancreatic Neoplasms 33Carcinoma, Renal Cell 33Myelodysplastic Syndromes 31Melanoma 30Leukemia, Lymphocytic, Chronic, B-Cell 29Triple Negative Breast Neoplasms 28Ovarian Neoplasms 27Lymphoma, Large B-Cell, Diffuse 25Glioblastoma 25Precursor Cell Lymphoblastic Leukemia-Lymphoma 24Urinary Bladder Neoplasms 22Lymphoma 22Burkitt Lymphoma 21Squamous Cell Carcinoma of Head and Neck 20Carcinoma, Hepatocellular 19Glioma 18Fallopian Tube Neoplasms 18Endometrial Neoplasms 17Oropharyngeal Neoplasms 15Mouth Neoplasms 15Lymphoma, Follicular 15Leukemia, Biphenotypic, Acute 15

Interventions

fludarabine phosphate 2Cyclophosphamide 2pevonedistat 1ibrutinib 1Specimen Handling 1Pharmacogenomic Variants 1Leukapheresis 1Etoposide 1Blood Component Removal 1Biopsy 1Bendamustine Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Prolymphocytic, B-Cell × Specimen Handling × 1 year × Clear all
NCT05418088 2026-05-29

Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies

Ohio State University Comprehensive Cancer Center

Phase 1 Recruiting
54 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Prolymphocytic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡